NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Forecast, Price & News $2.80 +0.10 (+3.70%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.67▼$3.0950-Day Range$1.96▼$2.8052-Week Range$1.86▼$6.99Volume243,364 shsAverage Volume109,771 shsMarket Capitalization$89.15 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lyra Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside614.3% Upside$20.00 Price TargetShort InterestHealthy0.06% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.19Based on 6 Articles This WeekInsider TradingAcquiring Shares$13.38 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.78) to ($1.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.71 out of 5 starsMedical Sector110th out of 983 stocksSurgical & Medical Instruments Industry11th out of 97 stocks 3.5 Analyst's Opinion Consensus RatingLyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.00, Lyra Therapeutics has a forecasted upside of 614.3% from its current price of $2.80.Amount of Analyst CoverageLyra Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.06% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently decreased by 31.40%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYRA. Previous Next 3.4 News and Social Media Coverage News SentimentLyra Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lyra Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for LYRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $13,378,133.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.42% of the stock of Lyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.20% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.78) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyra Therapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lyra Therapeutics (NASDAQ:LYRA) StockLyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Read More Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LYRA Stock News HeadlinesJune 3, 2023 | marketwatch.comStocks to Watch: Lyra Therapeutics, Natuzzi, SamsaraJune 2, 2023 | marketwatch.comLyra Therapeutics Shares Rise 11% as Investors Boost HoldingsJune 3, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.June 2, 2023 | finance.yahoo.comLyra Therapeutics to Present at Jefferies Healthcare ConferenceJune 1, 2023 | finance.yahoo.comLyra Therapeutics Announces Closing of $50.0 Million Private PlacementMay 26, 2023 | msn.comLyra Therapeutics announces $50M private placementMay 26, 2023 | finance.yahoo.comLyra Therapeutics Announces $50.0 Million Private PlacementMay 20, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Lyra Therapeutics, Inc. (NASDAQ:LYRA) Issued By William BlairJune 3, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 17, 2023 | americanbankingnews.comFY2023 Earnings Estimate for Lyra Therapeutics, Inc. (NASDAQ:LYRA) Issued By Cantor FitzgeraldMay 14, 2023 | finance.yahoo.comLyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2023 | benzinga.comLyra Therapeutics: Q1 Earnings InsightsMay 12, 2023 | finance.yahoo.comLyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 9, 2023 | finance.yahoo.comLyra Therapeutics to Present at Bank of America Securities 2023 Healthcare ConferenceApril 29, 2023 | finance.yahoo.comLyra Therapeutics, Inc.'s (NASDAQ:LYRA) biggest owners are retail investors who got richer after stock soared 18% last weekApril 25, 2023 | finance.yahoo.comLyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic RhinosinusitisApril 4, 2023 | americanbankingnews.comBrokers Issue Forecasts for Lyra Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:LYRA)March 31, 2023 | americanbankingnews.comWilliam Blair Weighs in on Lyra Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LYRA)March 30, 2023 | msn.comLyra Therapeutics's Return On Capital Employed InsightsMarch 30, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Lyra Therapeutics (LYRA)March 29, 2023 | msn.comLyra Therapeutics GAAP EPS of -$1.83 misses by $0.05, revenue of $1.36MMarch 29, 2023 | finance.yahoo.comLyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 20, 2023 | finance.yahoo.comEstimating The Intrinsic Value Of Lyra Therapeutics, Inc. (NASDAQ:LYRA)March 1, 2023 | finance.yahoo.comAssertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?February 28, 2023 | finance.yahoo.comLyra Therapeutics, Inc. (NASDAQ:LYRA) insiders placed bullish bets worth US$1.5m in the last 12 monthsFebruary 27, 2023 | msn.comLyra Therapeutics appoints chief technology officerFebruary 27, 2023 | finance.yahoo.comLyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology OfficerSee More Headlines LYRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYRA Company Calendar Last Earnings3/29/2023Today6/03/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LYRA CUSIPN/A CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees53Year FoundedN/APrice Target and Rating Average Stock Price Forecast$20.00 High Stock Price Forecast$20.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+614.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,280,000.00 Net Margins-5,032.86% Pretax Margin-5,020.64% Return on Equity-69.00% Return on Assets-52.71% Debt Debt-to-Equity RatioN/A Current Ratio5.99 Quick Ratio5.99 Sales & Book Value Annual Sales$1.36 million Price / Sales65.55 Cash FlowN/A Price / Cash FlowN/A Book Value$2.08 per share Price / Book1.35Miscellaneous Outstanding Shares31,840,000Free Float26,291,000Market Cap$89.15 million OptionableNot Optionable Beta-0.42 Key ExecutivesDr. Maria Palasis Ph.D. (Age 58)CEO, Pres & Director Comp: $848.19kMr. Jason Cavalier (Age 50)CFO, Treasurer & Sec. Comp: $464.11kMr. R. Donald Elsey MBA (Age 69)Advisor Comp: $640.11kMs. Corinne Noyes (Age 55)Sr. VP of Commercial Strategy & Market Devel. Comp: $426.73kDr. Harlan W. Waksal M.D. (Age 70)Exec. Chairman Dr. Carmichael S. Roberts Jr. (Age 54)Ph.D., Co-Founder Mr. Ray KnoxVP of OperationsDr. Robert Richard Ph.D. (Age 66)Sr. VP of Technical Operations Ms. Ellen CavaleriSr. VP of Investor Relations & CommunicationsMs. Vineeta Belanger Ph.D.Sr. VP of Clinical AffairsMore ExecutivesKey CompetitorsDelcath SystemsNASDAQ:DCTHProSomnusNASDAQ:OSANeuroneticsNASDAQ:STIMAkiliNASDAQ:AKLIMeihua International Medical TechnologiesNASDAQ:MHUAView All CompetitorsInsiders & InstitutionsPerceptive Advisors LlcBought 3,610,832 shares on 5/31/2023Total: $8.99 M ($2.49/share)Nbvm Gp, LlcBought 1,805,416 shares on 5/31/2023Total: $4.39 M ($2.43/share)Renaissance Technologies LLCBought 10,651 shares on 5/12/2023Ownership: 0.150%C Ann MerrifieldBought 4,000 shares on 6/10/2022Total: $20,200.00 ($5.05/share)View All Insider TransactionsView All Institutional Transactions LYRA Stock - Frequently Asked Questions Should I buy or sell Lyra Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LYRA shares. View LYRA analyst ratings or view top-rated stocks. What is Lyra Therapeutics' stock price forecast for 2023? 1 analysts have issued twelve-month price targets for Lyra Therapeutics' stock. Their LYRA share price forecasts range from $20.00 to $20.00. On average, they expect the company's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price. View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts. How have LYRA shares performed in 2023? Lyra Therapeutics' stock was trading at $3.14 at the start of the year. Since then, LYRA shares have decreased by 10.8% and is now trading at $2.80. View the best growth stocks for 2023 here. Are investors shorting Lyra Therapeutics? Lyra Therapeutics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 17,700 shares, a drop of 31.4% from the April 30th total of 25,800 shares. Based on an average daily volume of 38,000 shares, the days-to-cover ratio is currently 0.5 days. View Lyra Therapeutics' Short Interest. When is Lyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our LYRA earnings forecast. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its quarterly earnings data on Wednesday, March, 29th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.06. The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.36 million. Lyra Therapeutics had a negative trailing twelve-month return on equity of 69.00% and a negative net margin of 5,032.86%. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE). When did Lyra Therapeutics IPO? (LYRA) raised $52 million in an initial public offering (IPO) on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager. What is Lyra Therapeutics' stock symbol? Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA." Who are Lyra Therapeutics' major shareholders? Lyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.15%). Insiders that own company stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta, Nbvm Gp, Llc and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lyra Therapeutics' stock price today? One share of LYRA stock can currently be purchased for approximately $2.80. How much money does Lyra Therapeutics make? Lyra Therapeutics (NASDAQ:LYRA) has a market capitalization of $89.15 million and generates $1.36 million in revenue each year. The company earns $-55,280,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. How can I contact Lyra Therapeutics? Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.lyratherapeutics.com. The company can be reached via phone at 617-393-4600 or via email at laurence@gilmartinir.com. This page (NASDAQ:LYRA) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.